Drug Profile
Research programme: virus-like particle based immunotherapies - Stimunity
Alternative Names: STI-002 - Stimunity; STING agonists - Stimunity; STING agonists with VLP delivery; STING pathway enhancer; Virus-like particlesLatest Information Update: 28 Aug 2022
Price :
$50
*
At a glance
- Originator Stimunity
- Class Antineoplastics; Immunotherapies
- Mechanism of Action MPYS protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Aug 2022 No recent reports of development identified for preclinical development in Cancer in France (Parenteral)
- 25 Apr 2022 Stimunity establishes CRADA with National Cancer Institute for the development of STING in Cancer
- 21 Aug 2021 Stimunity and Portage Biotech plan clinical studies in Cancer in 2022 (Portage Biotech pipeline, August 2021)